{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"141.89","value":"38.7"},{"groupId":"OG001","spread":"57.51","value":"17.6"}]}],"title":"Week 4 (n:56, 28)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"60.62","value":"43.4"},{"groupId":"OG001","spread":"46.28","value":"-6.1"}]}],"title":"Week 12 (n:56, 29)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"75.83","value":"31.1"},{"groupId":"OG001","spread":"44.76","value":"-4.3"}]}],"title":"Week 24 (n:53, 29)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"45.07","value":"18.0"},{"groupId":"OG001","spread":"24.01","value":"5.4"}]}],"title":"Week 36 (n:26, 18)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"80.31","value":"55.3"},{"groupId":"OG001","spread":"34.55","value":"3.1"}]}],"title":"Week 48 (n:16, 8)"},{"categories":[{"measurements":[{"comment":"N/A = No patient was included at this time point, so no mean, no standard deviation (SD) could be calculated.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"N/A = only 1 patient was included, so no SD could be calculated","groupId":"OG001","spread":"NA","value":"-4.12"}]}],"title":"Week 60 (n:0, 1)"},{"categories":[{"measurements":[{"comment":"N/A = No patient was included at this time point, so no mean, no SD could be calculated.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"N/A = only 1 patient was included, so no SD could be calculated","groupId":"OG001","spread":"NA","value":"-6.1"}]}],"title":"Week 72 (n:0, 1)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"description":"Blood samples for biomarker assessment were collected immediately prior to study administration. On-treatment samples was compared to baseline samples with the change from baseline.","dispersionType":"Standard Deviation","groups":[{"description":"Study drug was given by continuous oral daily dosing of two 5 mg tablets.","id":"OG000","title":"Everolimus Randomized (Core Period)"},{"description":"Placebo was given by continuous oral daily dosing of two 5 mg tablets.","id":"OG001","title":"Placebo Randomized (Core Period)"}],"paramType":"MEAN","populationDescription":"The Full Analysis Set (FAS) is defined according to the Intention-to-Treat principle and consists of all randomized patients. The 'n' signifies those participants evaluable for this measure at specified time points for each group, respectively.","reportingStatus":"POSTED","timeFrame":"4 weeks, 12 weeks, 24 weeks, 36 weeks 48 weeks, 60 weeks, 72 weeks","title":"Change From Baseline in Plasma Angiogenic Molecules - Vascular Endothelial Growth Factor (VEGF) Marker","type":"SECONDARY","unitOfMeasure":"pg/mL"}